Emily Waldo

Emily Waldo

Auto-generated profile, based on publicly available information

Emily Waldo

Genomic Sciences and Systems Biology, Cleveland Clinic Research, Cleveland Clinic

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2025 in medRxiv
Verified
Preprint
Open access
PDF file
KSKathryn Step
Kathryn Step
TLThiago Peixoto Leal
Thiago Peixoto Leal
EWEmily Waldo
Emily Waldo
LMLusanda Madula
Lusanda Madula
YSYolandi Swart
Yolandi Swart
SBSORAYA BARDIEN
SORAYA BARDIEN
Genome-wide association studies (GWAS) have been successful in identifying over 100 loci associated with Parkinson’s disease (PD) susceptibility. However, the majority of these studies have focused on European cohorts with few including diverse ancestries. Using genotyped and imputed data from 691 South African PD cases and 826 controls, we conducted a conventional GWAS, two local ancestry GWAS (LA-GWAS) approaches (one using local ancestry as a covariate and the other separating the dosage per ancestry), and an association analysis to identify regions of homozygosity associated with PD status. Furthermore, we replicated these findings using another admixed population, a Latin American cohort (LARGE-PD). The ancestry inference suggested that the South African cohort is admixed from five populations, including African (AFR), European (EUR), Malaysian (MAL), Nama (NAMA), and South Asian (SAS), though with varying accuracy levels. The conventional GWAS successfully identified one locus (rs17098735-T) with genome-wide significance (p-value: 1.23×10 -8 ; beta= 2.286; SE= 0.401). Within the local ancestry window of the top GWAS hit, among individuals carrying the variant, 86.7% had AFR ancestry, 11% NAMA ancestry, and 2.2% MAL ancestry, with no EUR or SAS ancestry observed, highlighting a potential ancestry-specific genetic risk factor. Three lead loci were replicated in the LARGE-PD cohort. LA-GWAS using the Cochran-Armitage trend test identified 35 lead SNPs above suggestive significance after multiple test correction. Tractor-based approaches identified three lead loci when analyzing all five ancestry components jointly, as well as three additional lead loci in the AFR-only component, highlighting ancestry-specific loci that may contribute to genetic risk in diverse populations. For the LA-GWAS, one independent locus was replicated in LARGE-PD. Our findings suggest ancestry specificity in PD risk and underscores the importance of including diverse populations in genetics research. The study contributes towards a global understanding of the genetic etiology underlying PD.

27 August 2025 in medRxiv
Verified
Preprint
Open access
PDF file
HCHenry Mauricio Chaparro-Solano
Henry Mauricio Chaparro-Solano
DTDaniel Teixeira-Dos-Santos
Daniel Teixeira-Dos-Santos
EWEmily Waldo
Emily Waldo
TLThiago P. Leal
Thiago P. Leal
MIMiguel Inca-Martinez
Miguel Inca-Martinez
IMIgnacio F. Mata
Ignacio F. Mata
Background: Although levodopa remains the gold standard treatment for Parkinson’s disease (PD), its chronic use is associated with levodopa-induced dyskinesia (LID), a motor complication that impacts prognosis, quality of life, and treatment costs. Most known LID-associated factors have been identified in European-descendant populations. Objectives: To describe the epidemiology of LID in Latin American and Caribbean (LATAM) countries and assess the relevance of known and novel LID-associated factors in this population. Methods: We conducted a cross-sectional study using data from the Latin American Research consortium on the Genetics of Parkinson’s Disease (LARGE-PD). We included PD patients with information on LID status and levodopa use from eight LATAM countries. LID prevalence was calculated overall and by country. Countries were compared on demographic and clinical variables. Logistic regression was used to identify associations with LID. Results: A total of 3,695 PD patients (58.8% male) were included. Overall LID prevalence was 25.4% [95% CI: 24.06–26.87], ranging from 9.3% in Colombia to 45.1% in Puerto Rico. Prevalence increased progressively with longer disease duration. Country comparisons showed that not all known LID-associated factors explained prevalence differences. In logistic regression, fast disease progression was significantly associated with LID (OR: 1.55, 95%CI: 1.16–2.07), while sex was not (OR: 1.02, 95%CI: 0.87–1.18). Conclusions: This is the largest study on LID epidemiology in LATAM. While some known risk factors remain relevant, others, like sex, do not, underscoring the need for population-specific studies. Future work should integrate environmental, clinical, and genetic data to better understand LID mechanisms.

17 April 2026 in Journal of Parkinson’s Disease
Verified
Journal Article
Open access
HCHenry Mauricio Chaparro-Solano
Henry Mauricio Chaparro-Solano
DTDaniel Teixeira-Dos-Santos
Daniel Teixeira-Dos-Santos
EWEmily Waldo
Emily Waldo
TLThiago P Leal
Thiago P Leal
MIMiguel Inca-Martinez
Miguel Inca-Martinez
IMIgnacio F Mata
Ignacio F Mata
Background: Although levodopa is the gold standard treatment for Parkinson's disease (PD), its chronic use is associated with levodopa-induced dyskinesia (LID), a motor complication that impacts prognosis, quality of life, and treatment costs. Most known LID-associated factors have been identified in European-descendant populations. Objectives: To describe the epidemiology of LID in Latin American and Caribbean (LATAM) countries and assess the relevance of known and novel LID-associated factors in this population. Methods: We conducted a cross-sectional study using data from the Latin American Research consortium on the Genetics of Parkinson's Disease (LARGE-PD). We included PD patients with information on LID status and levodopa use from eight LATAM countries. LID prevalence was calculated overall and by country. Countries were compared on demographic and clinical variables. Logistic regression was used to identify associations with LID. Results: A total of 3695 PD patients (58.8% male) were included. Overall LID prevalence was 25.4% [95% CI: 24.06–26.87], ranging from 9.3% in Colombia to 45.1% in Puerto Rico. Prevalence increased progressively with longer disease duration. Country comparisons showed that not all known LID-associated factors explained prevalence differences. In logistic regression, fast disease progression was significantly associated with LID (OR: 1.55, 95%CI: 1.16–2.07), while sex was not (OR: 1.02, 95%CI: 0.87–1.18). Conclusions: This is the largest study on LID epidemiology in LATAM. While some known risk factors remain relevant, others, like sex, do not, underscoring the need for population-specific studies. Future work should integrate environmental, clinical, and genetic data to better understand LID mechanisms.

30 September 2025 in medRxiv
Verified
Preprint
Open access
PDF file
KSKathryn Step
Kathryn Step
CSCarene Anne Alene Ndong Sima
Carene Anne Alene Ndong Sima
SGSpencer Grant
Spencer Grant
JKJonggeol Jeffrey Kim
Jonggeol Jeffrey Kim
EWEmily Waldo
Emily Waldo
IMIgnacio F Mata
Ignacio F Mata
Parkinson’s disease (PD) is a complex neurodegenerative disorder with environmental and genetic influences. Using genotyping array data of 661 South African PD cases and 737 controls, a polygenic risk score (PRS) analysis was conducted using PRSice-2. Summary statistics were used from two PD association studies as base datasets. The target dataset was split into training (70%; n=979) and validation (30%; n=419) cohorts. Various clumping window sizes, linkage disequilibrium thresholds, and p -value thresholds were tested to determine the optimal combination for risk prediction. Additionally, we investigated the variance explained by different combinations of covariates. Finally, top contributing variants were identified and cross-referenced with inferred local ancestry to assess ancestry-specific effects. Overall, modest predictive performance was observed (AUC: 0.6307-0.6311). Age at recruitment was the strongest individual predictor, while sex contributed the least. Local ancestry analysis indicated that the top contributing variants were not ancestry-specific risk variants. These findings provide the first evaluation of PRS performance for PD in a highly admixed South African cohort, underscoring the importance of including underrepresented populations in genetic risk prediction.

27 December 2025 in medRxiv
Verified
Preprint
Open access
PDF file
KSKathryn Step
Kathryn Step
EWEmily Waldo
Emily Waldo
TLThiago Peixoto Leal
Thiago Peixoto Leal
MMMarla Mendes
Marla Mendes
SBSORAYA BARDIEN
SORAYA BARDIEN
IMIgnacio F Mata
Ignacio F Mata
X chromosome-wide association studies (XWAS) have successfully identified risk loci on the X chromosome associated with Parkinson’s disease (PD) susceptibility. However, only three such studies have been completed to date. Here, we present the first XWAS using an African cohort, comprising 690 PD cases and 826 controls. We applied an established XWAS workflow to perform male- and female-stratified analyses, as well as a combined meta-analysis. The male-stratified analysis identified five significant variants, including one lead locus (rs200539602), while the female-stratified analysis revealed 29 significant variants and two lead loci (rs2499550 and rs58045540), where rs2499550 is an upstream variant of the protein-coding gene FAAH2 . The remaining female-stratified significant variants are expression quantitative trait loci for SPIN2A, SPIN2B , and SPIN3 , which are highly expressed in the brain and nerve tissues, making them strong candidates for further investigation. One previously reported PD XWAS locus (rs28602900) was also replicated at a significance threshold of 0.05. The meta-analysis identified five variants surpassing chromosome-wide significance, including two lead loci (rs140715059 and rs141026964), the latter has no significant expression quantitative trait locus information but lies closest to the protein-coding gene MAGEC2 , which may warrant further follow-up. None of the meta-analysis signals replicated in prior neurodegenerative disease XWAS. Overall, this study provides novel insights into the contribution of the X chromosome to PD susceptibility and represents the first PD XWAS to include participants of African ancestry, highlighting the importance of extending genetic studies to diverse populations.

22 September 2026 in medRxiv
Verified
Preprint
Open access
PDF file
EWEmily Waldo
Emily Waldo
HCHenry Mauricio Chaparro-Solano
Henry Mauricio Chaparro-Solano
MIMariam Isayan
Mariam Isayan
TLThiago Peixoto Leal
Thiago Peixoto Leal
FDFelipe Duarte-Zambrano
Felipe Duarte-Zambrano
TDthe Latin American Research Consortium on the Genetics of Parkinson’s Disease
the Latin American Research Consortium on the Genetics of Parkinson’s Disease
Background: Parkinson’s disease (PD), the most common neurodegenerative movement disorder, is commonly thought of as an aging and sporadic disease; however, 5-14% of individuals experience disease onset before the age of 50 years (early-onset PD; EOPD) and about 20% have a positive family history. In the case of both EOPD and people with a family history of PD, evidence suggests higher rates of a disease-causing genetic contribution. Objectives: Our goal was to perform a variant screening of seven PD-related genes and 21 genes associated with related parkinsonian disorders to identify pathogenic/likely pathogenic variants and variants of uncertain significance within EOPD and family-history-positive individuals within the Latin American Research Consortium on the Genetics of PD (LARGE-PD). Methods: We performed short-read whole-genome sequencing on a subset of 263 individuals with EOPD and/or a familial history of PD who had no known pathogenic PD variant in genotyping data. Results: Of the analyzed individuals, a monogenic burden in primary and secondary PD genes due to pathogenic or likely pathogenic variants for PD was observed in 4.7%, an additional 5.5% had pathogenic or likely pathogenic variants for Gaucher’s disease, and 2.7% had known risk variants in GBA1 . Conclusions: By expanding the reported spectrum of disease-associated variants in a Latin American population, we identified previously unreported or underrepresented variants that would likely be missed by array-based or targeted screening approaches and contribute to the characterization of EOPD and familial PD in Latin America.